Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies

Muhammad A. Alvi; Maurice B. Loughrey; Philip Dunne; Stephen McQuaid; Richard Turkington; Marc-Aurel Fuchs; Claire McGready; Victoria Bingham; Brendan Pang; Wendy Moore; Perry Maxwell; Mark Lawler; Jacqueline A. James; Graeme I. Murray; Richard H. Wilson; Manuel Salto-Tellez

doi:10.1038/bjc.2017.168

Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies

Muhammad A. Alvi, Maurice B. Loughrey, Philip Dunne, Stephen McQuaid, Richard Turkington, Marc-Aurel Fuchs, Claire McGready, Victoria Bingham, Brendan Pang, Wendy Moore, Perry Maxwell, Mark Lawler, Jacqueline A. James, Graeme I. Murray, Richard H. Wilson, Manuel Salto-Tellez

Research output: Contribution to journal › Article

18 Citations (Scopus)

9 Downloads (Pure)

Abstract

BACKGROUND: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.

METHODS: Using test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used to test for adaptive immunity (CD3) and the immune checkpoint PDL1.

RESULTS: DNA methylation data split the cohorts into hypermethylated (n=18, 41%) and hypomethylated groups (n=26, 59%). The hypermethylated group predominant in the proximal colon was enriched for CpG island methylator phenotype (CIMP), BRAF V600E mutation and MSI (P<0.001). These cases also had a high CD3(+) immune infiltrate (P<0.001) and expressed PDL1 (P=0.03 in intra-tumoural lymphoid cells). The hypomethylated group predominant in the distal colon did not show any characteristic molecular features. We also detected a common targetable KIT mutation (c.1621A>C) across both groups. No statistically significant difference in outcome was observed between the two groups.

CONCLUSIONS: Our data show that SRCCa phenotype comprises two distinct genotypes. The MSI(+)/CIMP(+)/BRAF V600E(+)/CD3(+)/PDL1(+) hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can potentially be targeted by KIT inhibitors.British Journal of Cancer advance online publication, 8 June 2017; doi:10.1038/bjc.2017.168 www.bjcancer.com.

Original language	English
Pages (from-to)	203-209
Number of pages	7
Journal	British Journal of Cancer
Volume	117
Issue number	2
Early online date	8 Jun 2017
DOIs	https://doi.org/10.1038/bjc.2017.168
Publication status	Published - 11 Jul 2017

Keywords

KIT
genotype
PDL1

Access to Document

10.1038/bjc.2017.168Licence: CC BY-NC-SA

Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/
Final published version, 1.39 MBLicence: CC BY-NC-SA

Fingerprint Dive into the research topics of 'Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies'. Together they form a unique fingerprint.

Profiles

Graeme Murray

School of Medicine, Medical Sciences & Nutrition, Applied Medicine - Regius Chair of Pathology
Clinical Medicine
Institute of Medical Sciences

Person: Clinical Academic

Equipment

NHS Grampian Biorepository

Life Sciences

Research Facilities: Facility

Cite this

Alvi, M. A., Loughrey, M. B., Dunne, P., McQuaid, S., Turkington, R., Fuchs, M-A., McGready, C., Bingham, V., Pang, B., Moore, W., Maxwell, P., Lawler, M., James, J. A., Murray, G. I., Wilson, R. H., & Salto-Tellez, M. (2017). Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 117(2), 203-209. https://doi.org/10.1038/bjc.2017.168

Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. / Alvi, Muhammad A.; Loughrey, Maurice B.; Dunne, Philip; McQuaid, Stephen; Turkington, Richard; Fuchs, Marc-Aurel; McGready, Claire; Bingham, Victoria; Pang, Brendan; Moore, Wendy; Maxwell, Perry; Lawler, Mark; James, Jacqueline A.; Murray, Graeme I.; Wilson, Richard H.; Salto-Tellez, Manuel.

In: British Journal of Cancer, Vol. 117, No. 2, 11.07.2017, p. 203-209.

Research output: Contribution to journal › Article

Alvi, MA, Loughrey, MB, Dunne, P, McQuaid, S, Turkington, R, Fuchs, M-A, McGready, C, Bingham, V, Pang, B, Moore, W, Maxwell, P, Lawler, M, James, JA, Murray, GI, Wilson, RH & Salto-Tellez, M 2017, 'Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies', British Journal of Cancer, vol. 117, no. 2, pp. 203-209. https://doi.org/10.1038/bjc.2017.168

Alvi, Muhammad A. ; Loughrey, Maurice B. ; Dunne, Philip ; McQuaid, Stephen ; Turkington, Richard ; Fuchs, Marc-Aurel ; McGready, Claire ; Bingham, Victoria ; Pang, Brendan ; Moore, Wendy ; Maxwell, Perry ; Lawler, Mark ; James, Jacqueline A. ; Murray, Graeme I. ; Wilson, Richard H. ; Salto-Tellez, Manuel. / Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. In: British Journal of Cancer. 2017 ; Vol. 117, No. 2. pp. 203-209.

@article{d541416b7bea4331825c0bec5ec35755,

title = "Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies",

abstract = "BACKGROUND: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.METHODS: Using test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used to test for adaptive immunity (CD3) and the immune checkpoint PDL1.RESULTS: DNA methylation data split the cohorts into hypermethylated (n=18, 41%) and hypomethylated groups (n=26, 59%). The hypermethylated group predominant in the proximal colon was enriched for CpG island methylator phenotype (CIMP), BRAF V600E mutation and MSI (P<0.001). These cases also had a high CD3(+) immune infiltrate (P<0.001) and expressed PDL1 (P=0.03 in intra-tumoural lymphoid cells). The hypomethylated group predominant in the distal colon did not show any characteristic molecular features. We also detected a common targetable KIT mutation (c.1621A>C) across both groups. No statistically significant difference in outcome was observed between the two groups.CONCLUSIONS: Our data show that SRCCa phenotype comprises two distinct genotypes. The MSI(+)/CIMP(+)/BRAF V600E(+)/CD3(+)/PDL1(+) hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can potentially be targeted by KIT inhibitors.British Journal of Cancer advance online publication, 8 June 2017; doi:10.1038/bjc.2017.168 www.bjcancer.com.",

keywords = "KIT, genotype, PDL1",

author = "Alvi, {Muhammad A.} and Loughrey, {Maurice B.} and Philip Dunne and Stephen McQuaid and Richard Turkington and Marc-Aurel Fuchs and Claire McGready and Victoria Bingham and Brendan Pang and Wendy Moore and Perry Maxwell and Mark Lawler and James, {Jacqueline A.} and Murray, {Graeme I.} and Wilson, {Richard H.} and Manuel Salto-Tellez",

note = "We would like to thank all patients whose samples were used in this study. We are also thankful to the Northern Ireland Biobank and Grampian Biorepository for providing us with tissue blocks and patient data; and Dr HG Coleman (Queen{\textquoteright}s University Belfast) for her advice on statistical analyses. This work has been carried out with financial support from Cancer Research UK (grant: C11512/A18067), Experimental Cancer Medicine Centre Network (grant: C36697/A15590 from Cancer Research UK and the NI Health and Social Care Research and Development Division), the Sean Crummey Memorial Fund and the Tom Simms Memorial Fund. The Northern Ireland Biobank is funded by HSC Research and Development Division of the Public Health Agency in Northern Ireland and Cancer Research UK through the Belfast CRUK Centre and the Northern Ireland Experimental Cancer Medicine Centre; additional support was received from Friends of the Cancer Centre. The Northern Ireland Molecular Pathology Laboratory which is responsible for creating resources for the Northern Ireland Biobank has received funding from Cancer Research UK, Friends of the Cancer Centre and Sean Crummey Foundation. ",

year = "2017",

month = jul,

day = "11",

doi = "10.1038/bjc.2017.168",

language = "English",

volume = "117",

pages = "203--209",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies

AU - Alvi, Muhammad A.

AU - Loughrey, Maurice B.

AU - Dunne, Philip

AU - McQuaid, Stephen

AU - Turkington, Richard

AU - Fuchs, Marc-Aurel

AU - McGready, Claire

AU - Bingham, Victoria

AU - Pang, Brendan

AU - Moore, Wendy

AU - Maxwell, Perry

AU - Lawler, Mark

AU - James, Jacqueline A.

AU - Murray, Graeme I.

AU - Wilson, Richard H.

AU - Salto-Tellez, Manuel

N1 - We would like to thank all patients whose samples were used in this study. We are also thankful to the Northern Ireland Biobank and Grampian Biorepository for providing us with tissue blocks and patient data; and Dr HG Coleman (Queen’s University Belfast) for her advice on statistical analyses. This work has been carried out with financial support from Cancer Research UK (grant: C11512/A18067), Experimental Cancer Medicine Centre Network (grant: C36697/A15590 from Cancer Research UK and the NI Health and Social Care Research and Development Division), the Sean Crummey Memorial Fund and the Tom Simms Memorial Fund. The Northern Ireland Biobank is funded by HSC Research and Development Division of the Public Health Agency in Northern Ireland and Cancer Research UK through the Belfast CRUK Centre and the Northern Ireland Experimental Cancer Medicine Centre; additional support was received from Friends of the Cancer Centre. The Northern Ireland Molecular Pathology Laboratory which is responsible for creating resources for the Northern Ireland Biobank has received funding from Cancer Research UK, Friends of the Cancer Centre and Sean Crummey Foundation.

PY - 2017/7/11

Y1 - 2017/7/11

N2 - BACKGROUND: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.METHODS: Using test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used to test for adaptive immunity (CD3) and the immune checkpoint PDL1.RESULTS: DNA methylation data split the cohorts into hypermethylated (n=18, 41%) and hypomethylated groups (n=26, 59%). The hypermethylated group predominant in the proximal colon was enriched for CpG island methylator phenotype (CIMP), BRAF V600E mutation and MSI (P<0.001). These cases also had a high CD3(+) immune infiltrate (P<0.001) and expressed PDL1 (P=0.03 in intra-tumoural lymphoid cells). The hypomethylated group predominant in the distal colon did not show any characteristic molecular features. We also detected a common targetable KIT mutation (c.1621A>C) across both groups. No statistically significant difference in outcome was observed between the two groups.CONCLUSIONS: Our data show that SRCCa phenotype comprises two distinct genotypes. The MSI(+)/CIMP(+)/BRAF V600E(+)/CD3(+)/PDL1(+) hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can potentially be targeted by KIT inhibitors.British Journal of Cancer advance online publication, 8 June 2017; doi:10.1038/bjc.2017.168 www.bjcancer.com.

AB - BACKGROUND: Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.METHODS: Using test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used to test for adaptive immunity (CD3) and the immune checkpoint PDL1.RESULTS: DNA methylation data split the cohorts into hypermethylated (n=18, 41%) and hypomethylated groups (n=26, 59%). The hypermethylated group predominant in the proximal colon was enriched for CpG island methylator phenotype (CIMP), BRAF V600E mutation and MSI (P<0.001). These cases also had a high CD3(+) immune infiltrate (P<0.001) and expressed PDL1 (P=0.03 in intra-tumoural lymphoid cells). The hypomethylated group predominant in the distal colon did not show any characteristic molecular features. We also detected a common targetable KIT mutation (c.1621A>C) across both groups. No statistically significant difference in outcome was observed between the two groups.CONCLUSIONS: Our data show that SRCCa phenotype comprises two distinct genotypes. The MSI(+)/CIMP(+)/BRAF V600E(+)/CD3(+)/PDL1(+) hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can potentially be targeted by KIT inhibitors.British Journal of Cancer advance online publication, 8 June 2017; doi:10.1038/bjc.2017.168 www.bjcancer.com.

KW - KIT

KW - genotype

KW - PDL1

U2 - 10.1038/bjc.2017.168

DO - 10.1038/bjc.2017.168

M3 - Article

C2 - 28595259

VL - 117

SP - 203

EP - 209

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -